KRKA AT A GLANCE
In 70 years, we have grown from a domestic laboratory into one of the top-ranking global generic pharmaceutical companies.
Our competitive edge lies in our rich experience, development-oriented mentality, innovative solutions, high-quality generic medicines, continuous investment in advanced technologies and an extensive production, registration and marketing-and-sales network.
Our strategy positions us as a generic pharmaceutical company. Our reliable supply and output exceeding 16 billion tablets and capsules make us a strong partner to patients and healthcare systems in the treatment of most common diseases.
We generate more than €1.7 billion annually with sales of products and services placing us among the leading generic pharmaceutical companies in the world. Innovative generic products, investments and expansion to new markets warrant market share growth and good business performance.
We are committed to quality, innovation and development, and allocate 10% of revenue to research and development. When it comes to health, only the best is good enough. That is why we meticulously plan the development of each medicine. We control all its production phases, from the development of the active substance to the manufacture of the finished product, to ensure quality throughout its life cycle.